Effect of Gabapentin on Orthopedic Pain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01546857|
Recruitment Status : Terminated (No longer able to recruit subjects due to unavailability of orthopedic surgeon.)
First Posted : March 7, 2012
Last Update Posted : September 28, 2016
|Condition or disease||Intervention/treatment||Phase|
|Degenerative Joint Disease of Hip and Knee.||Drug: Placebo Drug: Gapabentin||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||The Effect of Gabapentin on Postoperative Pain: a Randomized, Double Blind, Placebo Controlled Trial|
|Study Start Date :||March 2012|
|Actual Primary Completion Date :||January 2016|
|Estimated Study Completion Date :||December 2016|
Placebo Comparator: placebo
Placebo one dose in the evening of surgery and post op day #1.
Active Comparator: Gabapentin
Gabapentin 400mg orally at 9pm on the evening of surgery and first day post operatively
400mg orally at 9pm day of surgery and the first evening post operatively.
Other Name: Neurontin
- The primary endpoint will be opioid consumption [ Time Frame: 48 hours ]Total opioid consumption and lowest/highest pain score in 8 hour segments.
- sleep scales [ Time Frame: 48 hours post operatively ]Pittsburgh Sleep Quality Index.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01546857
|United States, New Jersey|
|Newark, New Jersey, United States, 07101|
|Principal Investigator:||J. Daniel Eloy, MD||Rutgers/SUNJ|